In Immunology, the Safety Database Is the Program.
Regulatory and CMC leadership for autoimmune and inflammatory programs — where chronic dosing in non-fatal disease sets the safety bar.
The Molecule Clears Phase 2. The Safety Database Decides Approval.
Autoimmune and inflammatory diseases are chronic and rarely fatal. Patients take these drugs for years, often decades — and regulators judge them against that horizon. The efficacy signal is usually clear by Phase 2. What determines approval, labeling, and commercial life is whether the long-term safety database can carry the indication.
Serious infection, malignancy, and cardiovascular signals — the questions ORAL Surveillance forced onto the entire JAK class — have to be anticipated in the development plan, not discovered at the advisory committee. We build the safety and benefit–risk story into the program from the first protocol.
Chronic dosing in a non-fatal disease means the exposure and long-term follow-up expectations, not the response rate, set the timeline.
Every Immunology Approval Is a Balance the Reviewer Has to Defend.
Immunomodulation works by turning down the immune system — and the same mechanism that controls disease creates the risks the label must quantify. The whole program is an argument that one side of this scale outweighs the other.
Durable disease control
- Clinical remission and low disease activity that hold over years
- Steroid-sparing and prevention of irreversible structural damage
- Validated symptom endpoints — ACR20/50/70, PASI 75/90, endoscopic remission
- Patient-reported outcomes: pain, fatigue, and quality of life that matter to the label
The cost of immunosuppression
- Serious and opportunistic infection, including reactivation of latent disease
- Malignancy signals that require long-term, sometimes registry-based follow-up
- Cardiovascular and thromboembolic risk — the ORAL Surveillance legacy for JAKs
- Immunogenicity that erodes efficacy and, occasionally, safety
A Single Pathway Can Open a Portfolio of Indications.
The strongest immunology assets are lifecycle plays: one mechanism sequenced across autoimmune diseases, each indication its own trial design, endpoint, and benefit–risk case. The order you pursue them in is a regulatory decision, not just a commercial one.
Rheumatoid & Psoriatic Arthritis
The historical proving ground for immunology mechanisms — established endpoints, active-comparator expectations, and structural-damage imaging readouts.
Inflammatory Bowel Disease
Crohn's and ulcerative colitis, where central reading, histologic endpoints, and induction-plus-maintenance designs define the pivotal package.
Plaque Psoriasis & Dermatology
Fast, visible readouts that de-risk a mechanism early — often the first indication filed to establish the safety database for harder diseases.
Atopic Dermatitis & Asthma
Type 2 inflammation across skin and lung, where a single biologic can bridge specialties — and pediatric expectations arrive early.
Lupus & Systemic Disease
Heterogeneous, historically graveyard indications where endpoint selection and background-therapy control decide whether a trial can even read out.
Pediatric Autoimmune Disease
Juvenile arthritis, pediatric IBD and psoriasis, where the PSP/PIP and extrapolation strategy are set years before the adult filing.
The 2025 FDA draft guidance is retiring dedicated switching studies — reshaping how interchangeability is earned.
Immunology Is Where the Biosimilar Market Was Built — and Where the Rules Just Changed.
Anti-TNF and IL-inhibitor biosimilars turned immunology into the busiest 351(k) arena in medicine. The program lives or dies on the analytical similarity package: structure, function, and comparative immunogenicity carrying the weight that a full clinical program once did.
The FDA's 2025 draft guidance moves away from mandatory comparative efficacy trials and dedicated switching studies for interchangeability. We help both originators and biosimilar developers read that shift correctly — totality-of-evidence strategy, analytical similarity, and the immunogenicity comparison that still decides the file.
The Anti-Drug Antibody Strategy the FDA Expects, Tiered Correctly.
Every biologic provokes an immune response. What matters is whether your assay strategy characterizes it the way the agency's immunogenicity guidance demands — a validated cascade, not a single ELISA bolted on at the end.
Screening assay
A sensitive screen that flags every potentially antibody-positive sample, tuned to a defined false-positive rate.
Confirmatory assay
A specificity step that confirms true anti-drug antibodies and discards the screen's false positives.
Neutralizing assay
Determines whether the antibodies block drug activity — the response most likely to erode efficacy and safety.
Titer & impact
Magnitude, persistence, and correlation with PK, efficacy, and adverse events — the analysis that lands in the label.
Chronic Disease Means the Evidence Never Really Stops.
Approval in immunology is the start of an evidence obligation, not the end of one. Boxed warnings, registries, and pharmacovigilance commitments follow the molecule across every indication it earns.
of controlled and open-label exposure the agency expects for a chronically dosed immunomodulator — designed in from the start, per ICH E1.
safety findings can reshape your label overnight, as ORAL Surveillance did for every JAK inhibitor — anticipate the class read, don't be surprised by it.
and long-term post-authorization safety studies are routine commitments — build the pharmacovigilance and registry plan before approval, not after.
Six Failure Modes We Are Brought In to Prevent.
Efficacy is rarely the problem. These are.
An undersized safety database
A pivotal program powered for efficacy but short of the long-term exposure the indication's chronic use demands — the classic complete-response-letter theme in immunology.
Ignoring the class read
Designing as if your molecule is exempt from a class-wide infection, malignancy, or cardiovascular signal the division is already primed to look for.
Immunogenicity discovered late
An assay strategy that was not validated as a tiered cascade, leaving neutralizing-antibody and impact questions unanswered at filing.
Endpoint mismatch in hard indications
Lupus and IBD programs built on endpoints and background-therapy controls that cannot separate drug effect from noise.
A biosimilar similarity gap
Analytical or comparative-immunogenicity data that does not carry the totality of evidence now that clinical efficacy trials are being deprioritized.
A pediatric plan filed too late
Missing or misaligned PSP and PIP that delay the adult approval or forfeit extrapolation across the indication portfolio.
Immunology Regulatory Leadership That Has Defended the Benefit–Risk.
Our immunology leads have built long-term safety databases, prepared advisory committees on class safety signals, and filed biosimilars and interchangeables under the current and the changing rules.
"In immunology the reviewer is defending a benefit–risk balance to a committee. Our job is to hand them a file that already answers the safety question they were going to ask."
The posture we bring across the autoimmune and inflammatory portfolio — from first indication to interchangeability.
Developing an Immunology Asset? Build the Safety Story Before Phase 3 Locks.
Bring senior immunology regulatory leadership in while the safety database, endpoints, and indication sequence are still design choices.
Senior-led. Embedded in your team. No junior hand-offs.